Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Exelixis, Inc.NASDAQ: EXEL

Short-term Investments · Q2 FY2026 · quarter ended Jul 2026

Short-term investments falls 11.0% from a year ago

Short-term investments stood at $557.94M at the end of Q2 FY2026, down 11.0% from a year earlier and up 1.2% from the prior quarter. Over 3 fiscal years it compounded at -10.6% a year.

Context

  • Short-term investments amounted to 22.4% of total assets at the end of Q2 FY2026, down 1.0 pp from a year earlier.
  • Short-term investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps falling in the next quarterly balance sheet after a -11.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJul 2026
$557.94M+1.2% QoQ
Last fiscal yearJan 2026
$576.6M-35.5% YoY
Year agoJul 2025
$626.67M-11.0% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.0%——
1 year-35.5%——
3-year CAGR-10.6%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
576.6M USD
Year-over-year change
-35.5%
4-year CAGR
-8.4%

Short-term Investments vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's Jul 2026 short-term investments of $557.94M is the 3rd highest of the 8 companies compared; the peer median is $229.59M.
  • Its year-over-year change of -11.0% is the 6th highest of 8, against a peer median of +80.0%.
  • Short-term investments amounts to 22.4% of total assets for EXEL, versus a peer median of 24.2%.
EXEL Competitors Peer median
Short-term Investments for EXEL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RVMDRevolution Medicines, Inc.Jun 2026$3.12B +80.0%+50.3%72.2%
HCMHUTCHMED (China) LimitedDec 2025$1.3B +90.0%+59.8%73.9%
EXELExelixis, Inc.Jul 2026$557.94M -11.0%-10.6%22.4%
INCYIncyte CorporationJun 2026$553.37M +18.6%+18.9%7.0%
AZNAstraZeneca PLCSep 2026$229.59M +488.7%-27.0%0.2%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$221.17M -39.0%-12.1%46.8%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$122.27M +289.8%+50.2%24.2%
GMABGenmab A/SJun 2026$0 -100.0%—0.0%
Peer median (excluding EXEL) $229.59M+80.0%+34.5%24.2%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Cash & Equivalents647.17M501.2M262.99M217.37M482.49M
Short-term Investments819.91M807.27M732.31M893.9M576.6M
Net Receivables285.55M214.78M237.41M265.44M286.92M
Inventory27.49M33.3M17.32M22.39M21.69M
Other Current Assets54.63M62.21M67.93M68.48M75.6M
Total Current Assets1.83B1.62B1.32B1.47B1.44B
Property, Plant & Equipment (Net)104.03M345.44M470.85M359.11M441.27M
Goodwill63.68M63.68M63.68M63.68M63.68M
Intangible Assets00000
Long-term Investments371.11M756.73M728.72M637.29M603.6M
Tax Assets111.66M231.11M361.15M420.03M292.58M
Other Non-current Assets131M55.77M000
Total Non-current Assets781.49M1.45B1.62B1.48B1.4B
Total Assets2.62B3.07B2.94B2.95B2.84B
Account Payables24.26M32.67M33.77M38.19M29.62M
Short-term Debt00000
Tax Payables00000
Deferred Revenue7.81M7.49M000
Other Current Liabilities45.55M71.44M82.12M267.22M287.5M
Total Current Liabilities337.59M324.36M394.28M403.77M405.64M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.74M6.58M000
Other Non-current Liabilities8.02M61.95M94.22M108.9M104.42M
Total Non-current Liabilities68.03M258.7M284.17M299.72M277.46M
Total Liabilities405.62M583.06M678.45M703.49M683.1M
Common Stock319K324K303K282K262K
Retained Earnings(216.51M)(34.23M)(173.35M)(98.65M)(76.83M)
Accumulated OCI(758K)(14.52M)(3.75M)(1.35M)3.48M
Other Stockholders Equity00000
Minority Interest00000
Total Equity2.21B2.49B2.26B2.24B2.16B
Total Debt51.27M190.17M189.94M190.82M173.04M
Net Debt(595.9M)(311.03M)(73.05M)(26.55M)(309.45M)

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.